Press Releases | Regeneron Pharmaceuticals Inc.
WEBDupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD) Sep 26. Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024. Sep 20.
INVESTORS & MEDIA - Regeneron Pharmaceuticals Inc.
WEBAug 1, 2024 · Second quarter 2024 revenues increased 12% to $3 .55 billion versus second quarter 2023 Second quarter 2024 Dupixent ® global net sales (recorded by Sanofi) increased 27% to $3 .56 billion versus second quarter 2023 Second quarter 2024 U.S. net sales for EYLEA ® HD and EYLEA ® increased 2% to $1
Regeneron Announces Formation of Regeneron Cell Medicines …
WEBJan 30, 2024 · Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs. Regeneron to assume full development and commercialization rights for 2seventy bio’s preclinical and clinical stage cell therapy pipeline.
Novel Regeneron Bispecific Antibodies Show Encouraging Anti …
WEBNovel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors. First-in-class Phase 1 data presented at ESMO for ubamatamab (REGN4018; MUC16xCD3) in recurrent ovarian cancer and REGN5093 (METxMET) in MET-altered advanced non-small cell lung cancer.
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
WEB3 days ago · Dupixent is a key top-line driver for both Sanofi and Regeneron on strong demand trends. In the first half of 2024, Dupixent generated global product sales of $€6.1 billion, which were recorded ...
Regeneron Announces Encouraging Topline Phase 2 Data of High …
WEBAug 24, 2021 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that an ongoing Phase 2 proof-of-concept trial evaluating an investigational 8 mg dose of aflibercept met its primary safety endpoint, with no new safety signals observed compared to the currently-approved 2 mg dose of EYLEA ® …
Regeneron Reports First Quarter 2022 Financial and Operating …
WEBMay 4, 2022 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2022 and provided a business update.
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's …
WEBSanofi recorded 10.72 billion euros ($11.94 billion) in sales for Dupixent in 2023, which includes Regeneron's share. Analysts on average expect Dupixent, by far Sanofi's best-selling drug, to ...
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic …
WEB5 days ago · Currently, Regeneron's stock is trading at $1,063.05, up 2.22 percent, and Sanofi's stock is trading at $57.90, up 1.60 percent on the Nasdaq. SHARE THIS POST FACEBOOK
US FDA approves Regeneron's ultra-rare blood disease drug
WEBAug 18 (Reuters) - Regeneron Pharmaceuticals (REGN.O) said on Friday the U.S. health regulator approved its drug to treat a rare blood disease. The drug pozelimab, branded as Veopoz, would treat...